Table 5. Dose-limiting toxicities after the initial 6 weeks of cycle 1.

Patient ID	Treatment	Adverse Event	Event Onset	Causality	Action	Outcome
10011013	Tremelimumab 10 mg kg−1+PF-3512676 0.10 mg kg−1	Grade 3 colitis	Cycle 1, day 71	Tremelimumab	Permanent discontinuation of tremelimumab+PF-3512676	Resolved
10011016	Tremelimumab 10 mg kg−1+PF-3512676 0.15 mg kg−1	Grade 4 neutropenia Grade 4 rectal bleeding Grade 2 uveitis	Cycle 3, day 8 Cycle 4, day 28 157 days after completion of cycle 4	PF-3512676 Tremelimumab Tremelimumab	Permanent discontinuation of PF-3512676 Treatment complete	Resolved Resolved Resolved
10011018	Tremelimumab 10 mg kg−1+PF-3512676 0.15 mg kg−1	Grade 3 colitis	Cycle 2, day 12	Tremelimumab	Permanent discontinuation of tremelimumab+PF-3512676	Resolved